A paper by Dillibe et al. (2025), examined primary data obtained from 555 US-based patients who reported switching providers between 2018 and 2022. To analyze these data, the authors used critical incident technique (CIT). CIT is implemented by asking participants to recall and describe specific events or behaviors that contributed to important outcomes (in this…
This volume examines beliefs about bird flu and the false promotion of vitamin A as a measles prevention. It also covers social media content moderation and the misrepresentation of a study on gender-affirming care. Lastly, it explores when people prefer AI chatbots over humans for health information.
Healthcare organizations face challenges with siloed data, causing repeated paperwork
How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are working with the Trump administration to lower costs? The post Debunked Episode 21: The Drug Price Debate, AI in Healthcare Companies Face Consolidation But How Much? appeared first on MedCity News.
Waiv, formerly the diagnostics division of AI biotech Owkin, developed AI-enabled testing technologies that found use in clinical settings and in cancer drug research. Spinning out as an independent company enables Waiv to pursue its own growth strategy, co-founder and CEO Meriem Sefta said. The post Startup Waiv Spins Out of Owkin With $33M to…
Keith Poulsen’s jaw dropped when farmers showed him images on their cellphones at the World Dairy Expo in Wisconsin in October. A livestock veterinarian at the University of Wisconsin, Poulsen had seen sick cows before, with their noses dripping and udders slack. But the scale of the farmers’ efforts to treat the sick cows stunned…
CMS recently issued a statement saying that it’s continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see. The post Could the Trump Administration Change the Medicare Drug Price Negotiation Program? appeared…
Health-ISAC’s 2026 report warns of evolving threats like AI-driven attacks, sophisticated social engineering, and legacy device vulnerabilities
Experian Health’s High-Performance Summit (HPS) 2024 was the ultimate gathering for clients to connect, collaborate, and unlock the full potential of Experian Health solutions. Set in the vibrant “Lone Star State,” this exclusive client event brought together industry leaders to tackle some of healthcare’s biggest challenges, from cutting costs to revolutionizing financial and administrative outcomes….
It is not bringing down US prices, but delaying launches in Europe. Reuters reports: Drug launches in EU markets fell by some 35% in the 10 months since Trump’s executive order, compared with the previous 10 months…Delaying launches at lower EU prices could help secure higher U.S. prices for longer. You can read the full…